{"component": "definition", "props": {"groups": [{"samples": [{"hash": "k1AoM2m1OS9", "uri": "/contracts/k1AoM2m1OS9#actavis", "label": "Cash Bridge Credit and Guaranty Agreement (Actavis PLC)", "score": 25.501026694, "published": true}, {"hash": "8yYcLdtbrpv", "uri": "/contracts/8yYcLdtbrpv#actavis", "label": "Revolving Credit and Guaranty Agreement (Actavis PLC)", "score": 25.501026694, "published": true}, {"hash": "io6FbihE2rm", "uri": "/contracts/io6FbihE2rm#actavis", "label": "Term Loan Credit and Guaranty Agreement (Actavis PLC)", "score": 25.2518822724, "published": true}], "snippet_links": [{"key": "introductory-paragraph", "type": "definition", "offset": [33, 55]}], "snippet": "has the meaning specified in the introductory paragraph hereto.", "size": 5, "hash": "6416666c93186845627ffd72c0558edb", "id": 1}, {"samples": [{"hash": "cxVh9z522f3", "uri": "https://www.ftc.gov/system/files/documents/commission_decision_volumes/volume-154/ftc_volume_decision_154_jul_-_dec_2012pages_664-783.pdf", "label": "www.ftc.gov", "score": 8.1033538672, "published": false}, {"hash": "fz9u5D1L5sP", "uri": "https://www.ftc.gov/sites/default/files/documents/cases/2012/12/121214watsonactavisdo.pdf", "label": "www.ftc.gov", "score": 4.4757015743, "published": false}, {"hash": "fDNuxGt03TP", "uri": "https://www.ftc.gov/sites/default/files/documents/cases/2012/12/121015watsonactavisorder.pdf", "label": "www.ftc.gov", "score": 4.3935660507, "published": false}], "snippet_links": [{"key": "joint-ventures", "type": "definition", "offset": [185, 199]}, {"key": "each-case", "type": "definition", "offset": [251, 260]}, {"key": "not-limited", "type": "clause", "offset": [395, 406]}], "snippet": "means (i) Actavis Inc., (ii) Actavis Pharma Holding 4 ehf. and (iii) Actavis S.\u00e1.r.l., their directors, officers, employees, agents, representatives, successors, and assigns; and their joint ventures, subsidiaries, divisions, groups and affiliates in each case controlled by each of the following: (i) Actavis Inc., (ii) Actavis Pharma Holding 4 ehf. and (iii) Actavis S.\u00e1.r.l., (including, but not limited to, Actavis South Atlantic LLC, Actavis Pharma Mfg Pvt Ltd, and Actavis Elizabeth LLC) and the respective directors, officers, employees, agents, representatives, successors, and assigns of each.", "size": 4, "hash": "76e6a8473579d638a3108c6a8d8d0964", "id": 2}, {"samples": [{"hash": "kpFm0Rt7AJ2", "uri": "/contracts/kpFm0Rt7AJ2#actavis", "label": "Revolving Credit and Guaranty Agreement (Warner Chilcott LTD)", "score": 25.9719370294, "published": true}, {"hash": "aZq0SDDD7nO", "uri": "/contracts/aZq0SDDD7nO#actavis", "label": "Amendment Agreement (Warner Chilcott LTD)", "score": 25.9719370294, "published": true}, {"hash": "Hf4eAimNGz", "uri": "/contracts/Hf4eAimNGz#actavis", "label": "Term Loan Credit and Guaranty Agreement (Warner Chilcott LTD)", "score": 25.9719370294, "published": true}], "snippet_links": [{"key": "nevada-corporation", "type": "clause", "offset": [23, 41]}, {"key": "provided-that", "type": "clause", "offset": [83, 96]}, {"key": "agreement-and-the-other-loan-documents", "type": "clause", "offset": [179, 217]}, {"key": "in-accordance-with", "type": "definition", "offset": [218, 236]}, {"key": "pursuant-to", "type": "definition", "offset": [254, 265]}, {"key": "the-administrative-agent", "type": "definition", "offset": [307, 331]}, {"key": "ultimate-parent", "type": "definition", "offset": [336, 351]}], "snippet": "means Actavis, Inc., a Nevada corporation, and its successors permitted hereunder; provided that any successor shall expressly assume all of its rights and obligations under this Agreement and the other Loan Documents in accordance with Section 7.03 and pursuant to documentation reasonably satisfactory to the Administrative Agent and Ultimate Parent.", "size": 4, "hash": "0a736d808b99163079b58134ecafe6de", "id": 3}, {"samples": [{"hash": "b5crcPAvrpY", "uri": "/contracts/b5crcPAvrpY#actavis", "label": "Sublicense Agreement", "score": 31.340862423, "published": true}, {"hash": "BIXRO2PeD", "uri": "/contracts/BIXRO2PeD#actavis", "label": "Sublicense Agreement (Salix Pharmaceuticals LTD)", "score": 21.8542094456, "published": true}], "snippet_links": [{"key": "the-recitals", "type": "clause", "offset": [29, 41]}], "snippet": "has the meaning set forth in the recitals.", "size": 4, "hash": "e05541a00eeb1dba3509f49353d2d7e5", "id": 4}, {"samples": [{"hash": "3ELll6zMlMD", "uri": "https://www.ftc.gov/system/files/documents/cases/140630actavisforestdo.pdf", "label": "www.ftc.gov", "score": 8.5208761123, "published": false}, {"hash": "jrottTlKVDH", "uri": "https://www.ftc.gov/system/files/documents/cases/140905actavisdo.pdf", "label": "www.ftc.gov", "score": 8.1704312115, "published": false}, {"hash": "cLJofIkSJ8C", "uri": "https://www.ftc.gov/system/files/documents/cases/140630actavisforestorder.pdf", "label": "www.ftc.gov", "score": 5.2669404517, "published": false}], "snippet_links": [{"key": "joint-ventures", "type": "definition", "offset": [114, 128]}, {"key": "each-case", "type": "definition", "offset": [180, 189]}, {"key": "without-limitation", "type": "clause", "offset": [228, 246]}, {"key": "us-holding", "type": "definition", "offset": [254, 264]}, {"key": "the-acquisition", "type": "clause", "offset": [418, 433]}], "snippet": "means: Actavis plc, its directors, officers, employees, agents, representatives, successors, and assigns; and its joint ventures, subsidiaries, divisions, groups and affiliates in each case controlled by Actavis plc (including, without limitation, Tango US Holding Inc., and Watson Laboratories, Inc.), and the respective directors, officers, employees, agents, representatives, successors, and assigns of each. After the Acquisition, Actavis shall include Forest.", "size": 3, "hash": "72c016987c2afbc49990acedd51ea0b3", "id": 5}, {"samples": [{"hash": "lT2icvZlO8A", "uri": "https://www.ftc.gov/sites/default/files/documents/cases/2006/12/061212do_public_ver0610139.pdf", "label": "www.ftc.gov", "score": 3.0, "published": false}, {"hash": "fc2bpZgwB18", "uri": "https://www.ftc.gov/sites/default/files/documents/cases/2006/12/0610139ordermaintainassets.pdf", "label": "www.ftc.gov", "score": 3.0, "published": false}, {"hash": "fm1Lb21SIiu", "uri": "https://www.ftc.gov/sites/default/files/documents/cases/2006/10/0610139do_public_ver.pdf", "label": "www.ftc.gov", "score": 3.0, "published": false}], "snippet_links": [{"key": "limited-liability-company", "type": "definition", "offset": [31, 56]}, {"key": "doing-business", "type": "definition", "offset": [82, 96]}, {"key": "the-law", "type": "clause", "offset": [120, 127]}, {"key": "state-of-delaware", "type": "clause", "offset": [135, 152]}, {"key": "new-jersey", "type": "clause", "offset": [216, 226]}], "snippet": "means Actavis Elizabeth LLC, a limited liability company, organized, existing and doing business under and by virtue of the law of the State of Delaware, with its headquarters address at 990 Riverview Drive, Totowa, New Jersey 07512.", "size": 3, "hash": "9364fb1127fb6b6eeafc07be5ad1d2d2", "id": 6}, {"samples": [{"hash": "5hVwfI1RY4W", "uri": "/contracts/5hVwfI1RY4W#actavis", "label": "License Agreement", "score": 31.340862423, "published": true}, {"hash": "cWysIX9N17l", "uri": "/contracts/cWysIX9N17l#actavis", "label": "License Agreement (Salix Pharmaceuticals LTD)", "score": 21.8542094456, "published": true}], "snippet_links": [{"key": "state-of-delaware", "type": "clause", "offset": [50, 67]}], "snippet": "means Actavis Inc., a company incorporated in the State of Delaware.", "size": 3, "hash": "9ab8acd44babb33e11b8ec0c2ae88f34", "id": 7}, {"samples": [{"hash": "9N9ds9NgJzi", "uri": "/contracts/9N9ds9NgJzi#actavis", "label": "Loan and Security Agreement (Corium International, Inc.)", "score": 25.167008898, "published": true}, {"hash": "8VSEgp3Psif", "uri": "/contracts/8VSEgp3Psif#actavis", "label": "Loan and Security Agreement (Corium International, Inc.)", "score": 24.9753593429, "published": true}], "snippet_links": [], "snippet": "means Actavis South Atlantic LLC.", "size": 2, "hash": "717dc843b4c30b6aa0df137e472de9d2", "id": 8}, {"samples": [{"hash": "11B6ZGoYgI1", "uri": "https://www.sec.gov/Archives/edgar/data/1323854/000095010313003110/dp38371_ex9901.htm", "label": "News Release (Warner Chilcott PLC)", "score": 12.3812457221, "published": false}, {"hash": "hbP3gEMO3TT", "uri": "https://www.sec.gov/Archives/edgar/data/884629/000119312513228138/d541119dex991.htm", "label": "News Release (Actavis, Inc.)", "score": 10.3839835729, "published": false}], "snippet_links": [{"key": "nevada-corporation", "type": "clause", "offset": [23, 41]}], "snippet": "means Actavis, Inc., a Nevada corporation;", "size": 2, "hash": "b5b58123d595ad44b299d2a96243cc80", "id": 9}, {"samples": [{"hash": "de9P0G2Vukq", "uri": "/contracts/de9P0G2Vukq#actavis", "label": "Expense Reimbursement Agreement (Actavis, Inc.)", "score": 22.3894592745, "published": true}, {"hash": "dtssBTv4lye", "uri": "/contracts/dtssBTv4lye#actavis", "label": "Expense Reimbursement Agreement (Warner Chilcott PLC)", "score": 22.3812457221, "published": true}], "snippet_links": [{"key": "the-preamble", "type": "clause", "offset": [45, 57]}, {"key": "us-holdco", "type": "definition", "offset": [95, 104]}, {"key": "and-merger-sub", "type": "clause", "offset": [112, 126]}], "snippet": "shall have the meaning given to that term in the Preamble; \u201cActavis Parties\u201d, Actavis, Holdco, US Holdco, IrSub and Merger Sub;", "size": 2, "hash": "042ea90c51e352cec7d97e2c056fec7b", "id": 10}], "next_curs": "ClQSTmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjALEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIQYWN0YXZpcyMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Actavis", "snippet": "has the meaning specified in the introductory paragraph hereto.", "size": 48, "id": "actavis", "examples": ["<strong>Actavis</strong> Funding SCS, a limited partnership (soci\u00e9t\u00e9 en commandite simple) organized under the laws of the Grand Duchy of Luxembourg, having its registered office at \u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587 \u2587.\u2587.", "Non- Released Entities include, but are not limited to, Teva Ltd., Teva USA, Divested <strong>Actavis</strong> Generic Entities or other Divested Entities, and Anda.", "The Parties recognize that some of the Settling States, Participating Subdivisions, and Participating Special Districts are pursuing Claims against Teva Ltd., Teva USA, Cephalon, Divested <strong>Actavis</strong> Generic Entities, and/or other Divested Entities, and/or each of their respective parents, subsidiaries, and/or affiliates.", "The Settling States, Participating Subdivisions, and Participating Special Districts may reach a settlement agreement with Teva Ltd., Teva USA, Cephalon, Divested <strong>Actavis</strong> Generic Entities, and/or other Divested Entities, and/or each of their respective parents, subsidiaries, and/or affiliates that resolves some or all of their respective Claims.", "Allergan Funding SCS (formerly known as <strong>Actavis</strong> Funding SCS), a limited partnership (soci\u00e9t\u00e9 en commandite simple) organized under the laws of the Grand Duchy of Luxembourg, having its registered office at \u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587 \u2587.\u2587.", "<strong>Actavis</strong> Funding SCS a limited partnership (soci\u00e9t\u00e9 en commandite simple) organized under the laws of the Grand Duchy of Luxembourg, having its registered office at \u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587 \u2587.\u2587.", "If <strong>Actavis</strong> SCS fails to provide such unaudited interim financial statements or annual financial statements (as applicable) within twenty-one (21) Business Days as from the date of request by the Administrative Agent, the Administrative Agent may appoint (at the Loan Parties\u2019 expense) an independent auditor (r\u00e9viseur d\u2019entreprises agr\u00e9\u00e9), or an independent reputable investment bank, that shall undertake the determination of the relevant own funds and subordinated debts.", "This Deed supersedes any prior deed of indemnification or indemnification agreement between Indemnitee and the Company or its predecessors; provided, however, for the avoidance of doubt, that this Deed does not supersede or otherwise affect Indemnitee\u2019s rights under any indemnification agreement between Indemnitee and <strong>Actavis</strong> W.C. Holding Inc., a Delaware corporation and wholly-owned subsidiary of the Company.", "None of the Company, Intermediate Parent, <strong>Actavis</strong> Capital or, solely to the extent the successor Person thereto or the acquiring Person, as applicable, would be a Subsidiary of <strong>Actavis</strong> plc, <strong>Actavis</strong>, Inc.", "<strong>Actavis</strong> Funding SCS Term Credit Facility $5,500,000,000 of commitments 6."], "related": [["eg", "EG", "EG"], ["cci", "CCI", "CCI"], ["parent-holding-company", "Parent Holding Company", "Parent Holding Company"], ["acquisition-sub", "Acquisition Sub", "Acquisition Sub"], ["newco", "Newco", "Newco"]], "related_snippets": [], "updated": "2025-07-06T21:58:41+00:00"}, "json": true, "cursor": ""}}